BEIJING, Sept. 10, 2021 /PRNewswire/ -- Concord Medical
Services Holdings Limited ("Concord Medical" or the "Company")
(NYSE: CCM), a healthcare provider specialized in cancer treatment,
research, education, and prevention by establishing proton centers
and specialty cancer hospitals and operating an extensive network
of radiotherapy and diagnostic imaging centers in China, today announced that Shanghai Concord
Cancer Center ("SCCC", or the "planned hospital"), a business
subsidiary of an important operating platform of the Company,
Meizhong Jiahe Medical Science & Technology Development Group
Co., Ltd. ("Meizhong Jiahe"), has entered into an agreement (the
"Agreement") with CGN Medical Technology Ltd. ("CGNMT"), a
subsidiary of a China listed
company, which is an exclusive rights partner of Ion Beam
Applications ("IBA") in China for
its Proteus Plus technology. Pursuant to the Agreement, SCCC will
purchase the IBA's Proteus Plus system from CGNMT.
Situated in Shanghai New Hongqiao International Medical Center,
SCCC is a premium specialty cancer hospital constructed by the
Company and built in strict compliance with domestic tertiary
hospital standards, the highest standards for medical institutions
in China. The construction of the
planned hospital was commenced in September
2017 with an estimated construction period of five years. As
of the date of the Agreement, the planned hospital is still under
construction. The planned hospital will cover a site area of 70
acres, with the gross floor area of 158,769 square meters and over
400 beds. The Company aims to build the planned hospital with a
multi-disciplinary and standardized tumor diagnosis and treatment
service system that integrates domestic and international
technology and experience.
About Concord Medical
Concord Medical Services Holdings Limited is a healthcare
provider specialized in cancer treatment, research, education and
prevention. The Company operates a network of medically advanced
comprehensive cancer hospitals and standalone radiotherapy and
diagnostic imaging centres in China. The Company focuses on providing
multidisciplinary cancer care approach in all areas of oncology
services in its cancer hospitals. The Company also equips its
hospitals with technologically advanced equipment such as the
state-of-the-art proton therapy system in its premium cancer
hospitals in top-tier cities including Shanghai and Guangzhou. In addition, the Company saw the
opportunity of the expanding market of medical equipment in
China and developed its product
life-cycle management services form its existing medical equipment
and consumable sales services. As of December 31, 2020, the
Company operated a network of 27 radiotherapy centers and
diagnostic imaging centers, which are based in 20 hospitals,
established under long-term lease and management services
arrangements with the Company and spanning over 20 cities across 13
provinces and administrative regions in China. To ensure the
commitment to the highest standard of medical services for
patients, the Company offers ongoing education and training for
doctors and other medical professionals in its network hospitals
and centres in both domestic and overseas medical institutions.
For more information, please see http://ir.ccm.cn.
Safe Harbor Statement
This announcement contains forward-looking statements. These
forward-looking statements can be identified by words or phrases
such as "will," "expects," "anticipates," "future," "intends,"
"plans," "believes," "estimates" and similar expressions.
Forward-looking statements are inherently subject to uncertainties
and contingencies beyond the Company's control and based upon
premises with respect to future business decisions, which are
subject to change. A number of important factors could cause actual
results to differ materially from those contained in any
forward-looking statement. The Company does not undertake any
obligation to update any forward-looking statement, except as
required under applicable laws.
View original
content:https://www.prnewswire.com/news-releases/concord-medical-purchases-additional-proton-therapy-system-for-its-shanghai-concord-cancer-center-301373268.html
SOURCE Concord Medical Services Holdings Limited